On this page · 9 sections
Antiviral monoclonal antibodies intramuscular solution (100 mg/mL)

Palivizumab

Generic name: palivizumab

Brand names: Synagis, Synagis 50 mg/0.5 mL

Last updated November 3, 2026 0 views
Share

What is palivizumab?

Palivizumab is a man-made antibody that targets respiratory syncytial virus (RSV). RSV can lead to serious health issues in children. Palivizumab helps stop RSV cells from growing in the body.

Palivizumab is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants and infants born with certain lung problems or heart disease.

Palivizumab is most effective in children who are 24 months old or younger at the start of RSV season (6 months or younger for premature infants).

Palivizumab will not help a child who is already sick with RSV disease.

Palivizumab may also be used for other reasons not mentioned in this medication guide.

This section was rewritten for readability and reviewed for meaning.

How is palivizumab given?

Palivizumab is given as an injection into a muscle by a healthcare provider.

Palivizumab is administered once a month during the RSV season, which typically runs from November to April, but this may vary depending on your location.

To effectively help prevent RSV infection, your child's first palivizumab injection should be given before the RSV season starts.

During RSV season, your child should receive a palivizumab injection every 28 to 30 days. Each injection can help protect your child from RSV for about 1 month.

Make sure to attend all scheduled appointments for your child's injections. Even if your child becomes ill with RSV disease, they should continue to receive all planned palivizumab injections.

Palivizumab can lead to unusual results in some medical tests. Inform any doctor treating your child that they are using palivizumab.

This section was rewritten for readability and reviewed for meaning.

Warnings

Palivizumab should not be given to a child who has had a severe allergic reaction to palivizumab.

This section was rewritten for readability and reviewed for meaning.

Before taking this medicine

Palivizumab should not be given to a child who has had a severe allergic reaction to it.

Tell your doctor if your child has ever had:

  • a bleeding or blood clotting disorder; or
  • low levels of platelets in the blood.

This section was rewritten for readability and reviewed for meaning.

Palivizumab side effects

Get emergency medical help if your child has signs of an allergic reaction: hives, severe rash, itching; rapid or difficult breathing; blue-colored lips, skin, or fingernails; muscle weakness, being hard to wake up; swelling of the face, lips, tongue, or throat.

Common side effects of palivizumab may include:

  • fever; or
  • rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

This section was rewritten for readability and reviewed for meaning.

Palivizumab dosing information

Usual Pediatric Dose for Respiratory Syncytial Virus:

Pediatric patients 24 months of age or less:15 mg/kg IM once a month during RSV season (the first dose should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season)Comments:-Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season. -In the northern hemisphere, the RSV season typically commences in November and lasts through April, but it may begin earlier or persist later in certain communities.-Serum levels of this drug are decreased after cardiopulmonary bypass. Children undergoing cardiopulmonary bypass should receive an additional dose as soon as possible after the cardiopulmonary bypass procedure (even if sooner than a month from the previous dose). Thereafter, doses should be administered monthly as scheduled.Use: For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. The following points should be considered when prescribing this drug: -Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD).-Safety and efficacy have not been established for treatment of RSV disease.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your child's palivizumab injection.

This section was rewritten for readability and reviewed for meaning.

What happens if I overdose?

Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to happen.

Follow your doctor's instructions regarding any restrictions on food, drinks, or activities.

This section was rewritten for readability and reviewed for meaning.

What other drugs will affect palivizumab?

Other drugs may affect palivizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

This section was rewritten for readability and reviewed for meaning.

Related medicines

Before you take this medicine: the information on this page is general and may not cover your personal circumstances. Read the label supplied with your medicine and ask a pharmacist or doctor if you are unsure, especially if you are pregnant, breastfeeding, taking other medicines or managing a long-term condition.
General medicine information Consumer-friendly language

Content is provided for education and is not medical advice. See our medical disclaimer.